



Thoracic Transplantation: A Comprehensive Review

Kostka Tomasz*

Department of Acute and Tertiary Care, University of Pittsburgh, USA

Abstract

End-stage heart and respiratory failure can now be treated with heart and lung transplants. The International Society for Heart and Lung Transplantation (ISHLT)'s Registry states that heart and lung transplant recipients' survival and quality of life have improved as a result of numerous recent advancements. In the Russian Federation,

for diagnosis and target therapy of post-transplant complications.

Cardiovascular hypoxia, post-ischemic cardiac remodeling, and right ventricular hypertrophy and respiratory MiR-424. Additionally, miR-424 has the potential to suppress immune function and is involved in the regulation of

***Corresponding author:** Kostka Tomasz, Department of Acute and Tertiary Care, University of Pittsburgh, USA, E-mail: tomasz45@gmail.com

Received: 01-May-2023, Manuscript No: jcet-23-99259; **Editor assigned:** 04-May-2023, PreQC No: jcet-23-99259 (PQ); **Reviewed:** 18-May-2023, QC No: jcet-23-99259; **Revised:** 24-May-2023, Manuscript No: jcet-23-99259 (R); **Published:** 30-May-2023, DOI: 10.4172/2475-7640.1000166

Citation: Tomasz K (2023) Thoracic Transplantation: A Comprehensive Review. J Clin Exp Transplant 8: 166.

Copyright: © 2023 Tomasz K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

respective transfer, for certain special cases [8].

I

The indications for thoracic transplantation depend on the specific organ involved. Heart transplantation is indicated in patients with end-stage heart failure refractory to medical management. Lung transplantation is indicated in patients with end-stage lung disease, such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), and pulmonary hypertension (PH). Heart-lung transplantation is indicated in patients with end-stage disease of both organs [9].

E P

The evaluation process for thoracic transplantation involves a comprehensive assessment of the patient's medical history, physical examination, laboratory tests, imaging studies, and psychosocial evaluation. The evaluation process aims to identify potential contraindications, such as active infections, malignancy, severe liver or kidney disease, and psychosocial issues that may affect the patient's ability to comply with post-transplant care. The evaluation process also helps to determine the patient's candidacy for transplantation based on factors such as age, comorbidities, and the severity of the underlying disease [10].

S

The surgical technique for thoracic transplantation varies depending on the specific organ involved. Heart transplantation involves harvesting the donor heart and implanting it into the recipient's chest, connecting the new heart's blood vessels to the recipient's blood vessels and connecting the donor's heart valves to the recipient's native valves. In contrast, lung transplantation involves removing the native lungs and implanting the donor lungs, connecting the donor's bronchi to the recipient's trachea and the donor's pulmonary arteries and veins to the recipient's pulmonary vessels. Heart-lung transplantation involves removing the native heart and lungs and implanting the donor heart and lungs, connecting the donor's blood vessels, and bronchi to the recipient's blood vessels and trachea [11].

objective is to identify risk factors for postoperative TEA placement in lung transplant patients. The optional point of this study is to look at results between lung transplantation patients who got postoperative TEA situation and the people who didn't.

References

1. The pyogenic potential of the study. *Epidemiol Infect* 145:3065-3069.
2. The clinical features of respiratory infections caused by the *Streptococcus anginosus* group. *BMC Pulm Med* 26:115:133.
3. *PLoS One* 8:e63103.
4. Invasive *Streptococcus anginosus* group infection-does the species predict the outcome? *Int J Infect Dis* 18:38-40.
5. High-resolution CT. *Clin Radiol* 68:e331-337.
6. Gogineni VK, Modrykamien A (2011) Lung abscesses in 2 patients with . *Respir Care* 56:1966-1969.
7. Clinical analysis of cases of empyema due to *Streptococcus milleri* group. *Jpn J Infect Dis* 61:484-486.
8. Shinzato T, Saito A (1994) A mechanism of pathogenicity of "Streptococcus milleri group" in pulmonary infection: synergy with an anaerobe. *J Med Microbiol* 40:118-123.
9. Zhang Z, Xiao B, Liang Z (2020) Successful treatment of pyopneumothorax secondary to *Streptococcus constellatus* infection with linezolid: a case report and review of the literature. *J Med Case Rep* 14:180.
10. Che Rahim MJ, Mohammad N, Wan Ghazali WS (2016) Pyopneumothorax secondary to *Streptococcus milleri* infection. *BMJ Case Rep* bcr2016217537.
11. Xia J, Xia L, Zhou H, Lin X, Xu F (2021) Empyema caused by *Streptococcus constellatus*: a case report and literature review. *BMC Infect Dis* 21:1267.
12. An empyema caused by *Streptococcus constellatus* in an older immunocompetent patient: Case report. *Medicine* 100:e27893.
13. An empyema caused by *Streptococcus constellatus* in an older immunocompetent patient: Case report. *Medicine* 100:e27893.